Gå till innehåll

Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Norfloxacin

Summary

All medicinal products with norfloxacin have been withdrawn from the Swedish market.

 

Previously, there was some risk for the selection of antibiotic resistant bacteria in wastewater treatment plants in Sweden.

Studies have shown that even low concentrations of antibiotics in the environment may trigger antibiotic resistance and should therefore be taken to ensure that as little as possible end up in our environment.

References

  1. Goodpoint. Prioritering av läkemedel med miljörisk inom SLL. Stockholm: Goodpoint; 2016. Rapport LS 2016–0634.
  2. IVL Swedish Environmental Research Institute Ltd. Fick J, Lindberg RH, Kaj L, Brorström-Lundén E. Results from the Swedish National Screening Programme 2010. Subreport 3, B 2014 Pharmaceuticals.
  3. IVL Swedish Environmental Research Institute Ltd Fick J, Lindberg RH, Fång J, Magnér J, Kaj L, Brorström-Lundén E. Screening 2014. Analysis of pharmaceuticals and hormones in samples from WWTPs and receiving waters. Rapport C 135.
  4. Bengtsson-Palme J, Larsson DG. Concentrations of antibiotics predicted to select for resistant bacteria: Proposed limits for environmental regulation. Environ Int. 2016;86:140-9.
  5. Backhaus T, Scholze M, Grimme LH. The single substance and mixture toxicity of quinolones to the bioluminescent bacterium Vibrio fischeri. Aquat Toxicol. 2000;49:49-61.
  6. Gullberg E, Cao S, Berg OG, Ilbäck C, Sandegren L, Hughes D et al. Selection of resistant bacteria at very low antibiotic concentrations. PLoS Pathog. 2011;7:e1002158.
  7. Provtagningar av läkemedelsrester i vatten, sediment och fisk för Region Stockholm.
  8. Fass.se för vårdpersonal

Author: Health and Medical Care Administration, Region Stockholm